PDA announced today that senior leaders from the FDA's centers for drugs, biologics and veterinary medicine as well as the Office of Inspections and Investigations will participate in the plenary on Monday, Sept. 14, as part of the 2026 PDA/FDA Joint Regulatory Conference in Washington, D.C.

BETHESDA, Md., Aug. 28, 2026 /PRNewswire-PRWeb/ -- PDA announced today that senior leaders from the FDA's centers for drugs, biologics and veterinary medicine as well as the Office of Inspections and Investigations will participate in the plenary on Monday, Sept. 14, as part of the 2026 PDA/FDA Joint Regulatory Conference in Washington, D.C.

"The Center and Office Updates plenary are a staple of the PDA/FDA Joint Regulatory Conference," said Conference Co-Chair Mary E. Farbman, PhD, Associate Vice President, Global Quality Compliance, Merck & Co., Inc.. "It is unique to have the leaders of four FDA Centers and Offices assembled in one place for this essential conversation."

Conference Co-Chair Paul Z. Balcer, Consumer Safety Officer, OMQ, OC, CDER, U.S. FDA will moderate the session, which will offer firsthand insight into current Center activities, regulatory priorities, manufacturing and supply challenges, and issues affecting the broader pharmaceutical landscape.

Delegates will hear directly from:

• Michael Davis, MD, PhD, Acting Director, Center for Drug Evaluation and Research
• Timothy C. Schell, PhD, Director, Center for Veterinary Medicine
• Elizabeth P. Miller, PharmD, Associate Commissioner for Inspections and Investigations, Office of Inspections and Investigations
• Karim Mikhail, MSc, Acting Director, Center for Biologics Evaluation and Research

Following the updates, FDA leadership will come together for an extended 45-minute Q&A and roundtable discussion, providing attendees the opportunity to submit their questions to FDA leadership, opening the door to deeper discussion of the issues that matter most to the pharmaceutical community.

For more information, click here https://www.pda.org/global-event-calendar/event-detail/pda-fda-joint-regulatory-conference-2026

About PDA

The Parenteral Drug Association (PDA) is the leading global provider of science, technology, and regulatory information. PDA creates awareness and understanding of important issues facing the pharma community and delivers high-quality, relevant education to the industry. Since its founding in 1946 as a nonprofit organization, PDA has been committed to developing scientifically sound, practical technical information and expertise to advance pharma manufacturing science and regulation, so members can better serve patients.

Media Contact

Walter Morris, www.pda.org, 1 3016565900, morris@pda.org, www.pda.org

View original content to download multimedia:https://www.prweb.com/releases/us-fda-leadership-from-three-centers-and-oii-headline-the-center-office-updates-session-of-the-2026-pdafda-joint-regulatory-conference-302862992.html

SOURCE www.pda.org